Pharma Focus Asia

PharmaCyte Biotech Successfully Completes Manufacturing of Clinical Trial Product

Tuesday, October 15, 2019

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova Singapore (Austrianova), has completed the first of two staggered and back to back manufacturing runs for the production of PharmaCyte’s clinical trial product.

The first manufacturing run has been completed successfully. A representative sample of frozen syringes filled with the encapsulated cells inside are in the process of being shipped to external testing laboratories for the release testing of the clinical trial product that is required by the U.S. Food and Drug Administration (FDA). The clinical trial product will be used in PharmaCyte’s clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

Also, about two weeks ago, the second of the two manufacturing runs began. The cells from PharmaCyte’s Master Cell Bank (MCB) are reportedly growing well. The plan is to encapsulate them within the next week or two.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are exceedingly pleased that Austrianova has successfully manufactured PharmaCyte’s clinical trial product for our clinical trial in LAPC, and we’re equally as encouraged to hear that the second and final manufacturing run is proceeding as expected. During our recent shareholder update call, we committed to keeping our shareholders apprised of material developments related to PharmaCyte’s work in completing its Investigational New Drug application (IND). Today’s announcement is a major milestone towards the completion of that work.

“The efforts undertaken to meet this milestone were monumental and involved everyone associated with the technical aspects of the manufacturing process. We cannot be more thankful to our colleagues at Austrianova and those from PharmaCyte who were involved in the work. I feel strongly that we’re back on track to completing both of the required manufacturing runs that will generate the data needed to complete the IND.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024